UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **September 24, 2015**

SIENTRA, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	**001-36709**	**20-5551000**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

420 South Fairview Avenue, Suite 200
Santa Barbara, CA 93117
(Address of Principal Executive Offices and Zip Code)

(805) 562-3500
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On September 24, 2015, Sientra, Inc. (the " ***Company*** ") issued a letter to its plastic surgeon customers regarding the suspension of the CE certificate for all medical devices made by Silimed, the Company's contract manufacturer. A copy of the letter is filed as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Letter from Sientra, Inc. to its plastic surgeon customers, dated September 24, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

SIENTRA, INC.

Dated: September 24, 2015

By: /s/ Joel Smith
Joel Smith
General Counsel, Secretary and Chief Compliance Officer

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Letter from Sientra, Inc. to its plastic surgeon customers, dated September 24, 2015.

Exhibit 99.1

September 24, 2015

Dear Valued Plastic Surgeon,

I wanted to comment on some industry news that we became aware of yesterday. The Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the United Kingdom Department of Health, announced the suspension of Silimed's CE certificate for all medical devices made by Silimed. Notably, the MHRA stated in its announcement that ***"there has been no indication at this time that these issues would pose a threat to patient safety."***

As you may know, Silimed is one of our contract manufacturers. Please note that the MHRA announcement has no applicability to Sientra's products as it is applicable only to the distribution of Silimed's CE-marked implants in Europe. Our products are FDA-regulated and PMA-approved. Sientra's breast implants and our other products continue to be marketed and available in the United States and there has been no change to the regulatory status of Sientra's FDA-approved breast implants.

We are confident in the safety of our products, and you can reassure your patients as needed by telling them that there has been no indication that these issues would pose a threat to their safety. In light of this news, we will of course conduct our own review to ensure continued compliance with our own high internal standards.

A few other important items to note:

- Silimed has assured us that they are working with the MHRA in the European Union to resolve the issues promptly; and
- Silimed has been audited multiple times by the FDA to ensure compliance with the Quality Systems Regulation, and has, to date, never received a 483 observation. Silimed has also been audited by ANVISA and other Brazilian regulatory authorities.

Our recent publication of our clinical data at 8-years of follow-up supports our continued record of safety and efficacy.

Given our unwavering commitment to you and your patients, I will continue to keep you fully informed.

In the meantime, and as always, I am available along with my team to address your needs and inquiries. Please do not hesitate to contact us via our information request line at info@sientra.com, or by calling us at 888.708.0808.

Respectfully,

Hani Zeini
Founder and Chief Executive Officer
Sientra, Inc.